Compounded tirzepatide is a custom-mixed version of the same active ingredient found in Mounjaro and Zepbound, prepared by pharmacies rather than by Eli Lilly. It exploded in popularity during the tirzepatide shortage, but after the FDA declared that shortage resolved in late 2024, large-scale compounding of copies became unlawful through 2025.
What exactly is compounded tirzepatide?
Compounding is the practice of a licensed pharmacy mixing a medication to order, typically from raw active pharmaceutical ingredient, rather than dispensing a manufacturer's finished product. Compounded tirzepatide is usually supplied as a multi-dose vial plus syringes instead of a prefilled pen, and it is often combined with additives such as vitamin B6 or niacinamide. Crucially, compounded products are not FDA-approved; the agency does not review them for safety, effectiveness, or quality before they reach patients.
Why did compounded tirzepatide exist in the first place?
US law lets pharmacies compound a drug that is essentially a copy of a commercial product only under narrow conditions, and one of those is when the brand drug is officially in shortage. Tirzepatide spent much of 2022 to 2024 on the FDA shortage list as demand for Mounjaro and Zepbound outran supply. During that window, 503A pharmacies and 503B outsourcing facilities could legally produce tirzepatide, and a large telehealth market grew up around cheaper compounded vials. That legal opening was always tied to the shortage continuing.
How was compounded tirzepatide typically supplied?
Unlike the brand pens, compounded tirzepatide almost always arrived as a glass vial of liquid, or occasionally a powder for the patient to reconstitute, alongside a pack of insulin syringes. Patients drew their own dose in units, which suits fine-tuned microdosing but introduces measurement error that prefilled pens are designed to eliminate. Many telehealth platforms paired the vials with a brief online intake and shipped on a monthly subscription, and that frictionless model is a large part of why the compounded market scaled so fast during the shortage. The flip side of the convenience was inconsistency: concentration, additives, and fill volume varied from one pharmacy to the next, so two people both using "compounded tirzepatide" might be on meaningfully different products at meaningfully different strengths.
What happened when the FDA ended the shortage?
The FDA removed tirzepatide from its shortage list on December 19, 2024, declaring supply resolved. That decision triggered a phased wind-down for compounders, because the legal basis for copying the drug disappeared along with the shortage.
| Date | Event |
|---|---|
| Dec 19, 2024 | FDA declares the tirzepatide shortage resolved |
| Feb 18, 2025 | Enforcement discretion ends for 503A pharmacies |
| Mar 19, 2025 | Enforcement discretion ends for 503B outsourcing facilities |
| 2026 | FDA proposes excluding tirzepatide from the 503B bulk-substances list |
Industry groups challenged these deadlines in federal court, but judges denied their requests to pause enforcement, so the dates held.
Is compounded tirzepatide legal in 2026?
The blanket, shortage-era permission to mass-produce tirzepatide copies is gone. What survives is the much narrower, long-standing authority for a 503A pharmacy to compound for an individual patient when there is a documented clinical need that the FDA-approved product cannot meet, for example a verified allergy to an inactive ingredient in the commercial pen. Routine "we compound tirzepatide for everyone" operations no longer have a legal shield. Because sourcing is now the central question, it is worth understanding how to evaluate a tirzepatide compounding pharmacy before trusting any supplier.
It is also worth separating "legal" from "FDA-approved." Even a properly compounded, patient-specific preparation remains a non-approved product; legality in that narrow case rests on documented medical necessity, not on the product having been tested and cleared like Mounjaro or Zepbound. That distinction matters if you are weighing safety, insurance coverage, or what happens if something goes wrong, since compounded drugs sit largely outside the manufacturer-liability and recall systems that cover approved medicines.
How does compounded tirzepatide compare to brand Mounjaro and Zepbound?
The active molecule can be the same, but the differences around it matter.
| Feature | Brand (Mounjaro / Zepbound) | Compounded tirzepatide |
|---|---|---|
| FDA approval | Yes | No |
| Manufacturer | Eli Lilly | Compounding pharmacy |
| Form | Prefilled single-dose pen | Multi-dose vial + syringes |
| Dose accuracy | Fixed, factory-controlled | Depends on user drawing units |
| Quality oversight | Full FDA review | Pharmacy/state oversight only |
| Typical cost | Higher (often insurance-dependent) | Often lower out of pocket |
Cost was the engine behind the entire compounded market. During the shortage, a month of compounded vials often ran a few hundred dollars or less through telehealth, while a brand pen without insurance could list at well over a thousand dollars a month. That gap is what pulled cash-pay patients toward vials in the first place. Since the shortage ended, Eli Lilly has expanded self-pay pricing on single-dose Zepbound vials to close some of that distance, so the savings that once offset the risk of an unapproved product are smaller now than they were at the peak of compounding.
For the approved branded options, see our Mounjaro guide and Zepbound guide. If you already hold compounded vials, our explainer on whether compounded tirzepatide expires covers storage and dating.
What are the risks of compounded tirzepatide?
The FDA has repeatedly warned about compounded GLP-1 drugs, citing dosing errors from patients measuring their own units, the use of unapproved salt forms of the active ingredient, and products from facilities it has not inspected. Without standardized fill volumes, an accidental tenfold overdose is a real and documented hazard. There is also no guarantee the vial contains the stated amount or purity of tirzepatide, since the finished product never passed FDA review. Reconstitution and storage add further room for error, because the safety of a vial depends on the patient handling it correctly over weeks of use rather than on a sealed, single-use pen.
Who was affected when the compounding rules changed?
The 2025 wind-down landed hardest on the large population of cash-pay and telehealth patients who had come to depend on lower-cost vials. As enforcement discretion ended, many compounding pharmacies and telehealth companies stopped offering tirzepatide outright or steered patients toward the branded products, manufacturer savings programs, or different molecules entirely. Some providers floated personalized-dose or combination formulations to argue a patient-specific clinical need, but the FDA and the courts have signaled little tolerance for arrangements that function mainly as a workaround to keep mass compounding alive. For most people the practical choice narrowed to transitioning onto FDA-approved Mounjaro or Zepbound, often with the help of self-pay vial pricing now offered through manufacturer channels, or stopping treatment.
References
- FDA: clarifying policies for compounders as GLP-1 supply stabilizes
- FDA Mounjaro (tirzepatide) prescribing information
Frequently Asked Questions
Is compounded tirzepatide the same drug as Zepbound?
It can share the same active ingredient, but it is not the same product. Zepbound is FDA-approved and factory-filled; compounded tirzepatide is not reviewed by the FDA and is mixed by a pharmacy.
Can I still buy compounded tirzepatide after the shortage ended?
Mass-market compounded copies lost their legal basis in early 2025. Narrow, patient-specific compounding may continue only when a documented clinical need cannot be met by the approved product.
Why was compounded tirzepatide cheaper?
It skipped brand pricing and was often sold cash-pay through telehealth. That lower price came without FDA approval, standardized dosing, or the same quality oversight.
Is compounded tirzepatide safe?
The FDA has not verified its safety. Reported risks include self-measured dosing errors, unapproved ingredient forms, and uninspected manufacturing.
This article is educational and does not constitute medical or legal advice; confirm current rules with a licensed clinician.
